There has been a long-standing consensus on the principles that should guide screening asymptomatic individuals whether for treatment, counseling, or research. Advances in molecular biology will increase the rate of new opportunities for such screening. The benefits and risks, for individuals as well as the public health, will vary with each new test. As with all new technologies, these benefits and risks will have to be assessed in well-designed and well-reviewed studies if individuals are to be allowed to make informed decisions regarding whether or not to be tested.
作者:N, Fost
来源:FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1992 年 6卷 10期